Plain-English translation of NCT06544785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether zanubrutinib combined with can effectively treat chronic lymphocytic leukemia or small lymphocytic lymphoma in patients who have never received treatment before. The study is comparing two different schedules for adding the second medication: starting it early (at the beginning of treatment) versus starting it later (after 12 cycles). The goal is to find the best timing to maximize how well the treatment works while minimizing side effects.
Currently, patients with these types of blood cancers have limited treatment options, and doctors want to find the most effective combination and schedule of these medications. This trial is designed to help determine whether starting the second medication early in treatment or later produces better results.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. Both groups take a daily oral medication. In one group, you receive intravenous infusions of the second medication starting at cycle 2; in the other group, you start those infusions after 12 cycles of the first medication alone. Your response to treatment will be checked at cycle 20. If your cancer reaches a very deep remission (nearly undetectable cancer cells), you may stop treatment. Otherwise, you will continue taking medication until your disease gets worse, side effects become unacceptable, or the study ends. You will attend regular clinic visits across multiple centers in Spain over approximately 18–20 months of active treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Spain